Welcome to our dedicated page for Silexion Therapeutics news (Ticker: SLXN), a resource for investors and traders seeking the latest updates and insights on Silexion Therapeutics stock.
Silexion Therapeutics Corp (NASDAQ: SLXN) is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, with a lead focus on locally advanced pancreatic cancer. The news flow around Silexion centers on its progress with SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes that drive aggressive solid tumors.
Readers following SLXN news can expect updates on preclinical data, regulatory milestones, and clinical trial preparations. Recent press releases have highlighted new human cancer cell line results demonstrating high inhibition across multiple KRAS mutations and organ sites, including pancreatic, colorectal, lung, and gastric cancer models. The company has also reported biodistribution and efficacy data in metastatic pancreatic cancer models, as well as completion of two-species toxicology studies that it states confirmed no systemic organ toxicity.
Another key theme in Silexion’s news is its regulatory and clinical development pathway for SIL204. The company has announced formal written Scientific Advice from Germany’s Federal Institute for Drugs and Medical Devices (BfArM) on the design of its planned Phase 2/3 trial in locally advanced pancreatic cancer, submission of a clinical trial application in Israel, and plans for additional submissions in Europe and the United States. Operational updates include selection of a contract research organization, manufacturing collaborations, and preparations for trial initiation.
In addition, Silexion’s news releases cover financing transactions, capital-raising activities, and Nasdaq listing matters, such as regaining compliance with minimum bid price and shareholders’ equity requirements. Investors and observers can use this news page to review company communications on scientific results, regulatory interactions, business developments, and conference presentations related to Silexion’s KRAS-focused RNAi oncology programs.
Silexion Therapeutics (NASDAQ: SLXN) has announced a strategic collaboration with Catalent for the formulation development and clinical manufacturing of SIL204, their next-generation siRNA candidate. The partnership will utilize Catalent's Limoges facility in France to optimize both systemic and intratumoral delivery formulations of SIL204.
The collaboration follows Silexion's recent preclinical breakthrough showing SIL204's efficacy in reducing primary tumor growth and metastatic spread in pancreatic cancer models. SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, and G13D) important in pancreatic, colorectal, and lung cancers.
The company aims to initiate human clinical trials in H1 2026, with plans for regulatory submissions to the Israel Ministry of Health in H2 2025 and to the European Union in H1 2026. Throughout 2025, Silexion will conduct additional toxicology and pharmacodynamic studies as part of their comprehensive development strategy.
Silexion Therapeutics (NASDAQ: SLXN) has announced an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven pancreatic cancer. The new strategy combines both intratumoral and systemic administration approaches to target primary tumors and metastases.
The expansion follows promising preclinical data showing significant tumor growth inhibition in orthotopic models through systemic administration. Recent studies demonstrated SIL204's ability to reduce metastases to secondary organs, with pharmacokinetic data showing sustained drug levels for approximately two months after a single subcutaneous dose.
The development roadmap includes:
- Additional toxicology and pharmacodynamic studies throughout 2025
- Planned regulatory submissions to Israel Ministry of Health in H2 2025
- European Union submission targeted for H1 2026
- Human trials initiation planned for H1 2026
Silexion Therapeutics has completed an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The plan will be presented at the NeauxCancer 2025 Conference in New Orleans from March 27th-29th, 2025.
The strategic plan, building on recent promising preclinical data, aims to maximize SIL-204's potential across multiple delivery approaches. The company's presentation is scheduled for March 28th at 1:00pm during the conference's Innovation track, where they will present their strategic vision alongside recently reported preclinical findings.
The clinical-stage biotechnology company, specializing in RNA interference (RNAi) therapies, will focus particularly on pancreatic cancer in their comprehensive approach to targeting KRAS-driven cancers.
Silexion Therapeutics (NASDAQ: SLXN) reported its financial results for 2024, marking a transformative year highlighted by its Nasdaq listing and advancement in RNAi therapies for KRAS-driven cancers. The company's second-generation candidate SIL204 showed promising results in reducing tumor burden and metastatic spread in pancreatic cancer models.
Key financial highlights include:
- Cash position of $1.2M as of December 31, 2024 (down from $4.6M in 2023)
- Total operating expenses increased to $12.6M (from $4.7M in 2023)
- Net loss of $16.5M (compared to $5.1M in 2023)
- Recent funding raised approximately $9.1M gross proceeds ($7.9M net)
Clinical highlights include a 56% objective response rate in Phase 2 LODER™ trial for pancreatic cancer patients with KRAS mutations, and plans to initiate SIL204 Phase 2/3 trials by first half of 2026.
Silexion Therapeutics (NASDAQ: SLXN) has reported breakthrough preclinical data for its SIL204 therapeutic candidate, showing promising results in treating KRAS-driven cancers, particularly pancreatic cancer. The orthotopic model studies demonstrated:
- ~70% reduction in tumor cell bioluminescence in AsPC-1 model (KRAS G12D mutation)
- Dose-dependent tumor cell reductions in Panc-1 model
- Up to 80% overall tumor cell reduction in BxPC-3 model
Notably, this marks the first systematic validation of a therapy's ability to suppress metastatic spread through systemic administration. The precision medicine market is projected to grow from $102 billion in 2024 to $470 billion by 2034. Maxim Group maintains a 'Buy' rating with a $9 price target, representing a ~600% premium over current price. The company is preparing to unveil an expanded development plan for SIL204, potentially exploring broader clinical applications.
Silexion Therapeutics (NASDAQ: SLXN) announced positive initial data from orthotopic pancreatic cancer models for their SIL204 treatment. The study demonstrated that subcutaneously administered SIL204 effectively reduces both primary tumor growth and metastatic spread.
Key findings include:
- ~70% reduction in tumor cell numbers in AsPC-1 (KRAS G12D mutation) by day 28
- In Panc-1 (KRAS G12D), tumor cells decreased 12% while control group increased >100% by day 14
- ~80% reduction in BxPC-3 (KRAS wild-type) by day 28
- Significant reduction in metastatic spread across liver, intestine, spleen and stomach in Panc-1 and BxPC-3 models
The results validate SIL204's efficacy in a more clinically relevant setting, where human pancreatic tumor cells are implanted directly into the pancreas. The company is finalizing an updated development strategy based on these findings.
Silexion Therapeutics (NASDAQ: SLXN) is approaching a important milestone with upcoming orthotopic pancreatic cancer model data for its SIL-204 therapy. The study evaluates the treatment's effectiveness in reducing primary tumor growth and inhibiting metastatic spread in pancreatic cancer models.
Previous studies have shown promising results, with SIL-204 demonstrating a 50% reduction in tumor growth and complete necrosis in half of treated tumors. The therapy has maintained therapeutic levels for over 56 days from a single dose. The RNAi-based approach targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, and G13D), potentially offering broader therapeutic benefits than existing treatments.
The data readout, expected in March 2025, could validate systemic efficacy against metastatic disease for the first time. Maxim Group maintains a $9 price target and strong buy rating on SLXN, citing the company's clinical trajectory and RNAi platform validation.
Silexion Therapeutics (NASDAQ: SLXN) has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, marking the first systematic evaluation of this RNA interference therapy administered subcutaneously in clinically relevant models.
The study assessed two critical aspects of SIL-204's potential:
- Ability to reduce primary tumor growth when administered systemically
- Capacity to reduce metastatic spread from orthotopic tumors to secondary organs
Unlike standard subcutaneous xenograft models, the orthotopic models used in this study better represent the complex microenvironment of pancreatic tumors and their metastatic behavior by allowing tumors to develop in their native environment.
Data analysis is currently underway, with initial results expected to be reported in March 2025. These findings will inform Silexion's development strategy for SIL-204 in addressing both localized and metastatic pancreatic cancer.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNAi therapies for KRAS-driven cancers, has announced agreements for the immediate exercise of outstanding warrants. The exercise involves 2,221,523 ordinary shares at $1.35 per share, expected to generate approximately $3.3 million in gross proceeds.
The company will issue new unregistered warrants to purchase an additional 2,221,523 ordinary shares at $1.50 per share, exercisable immediately upon issuance with a 24-month term. Warrant holders will pay an additional $0.125 per new warrant, contributing $277,690.38 to the gross proceeds. H.C. Wainwright & Co. serves as the exclusive placement agent, and the offering is expected to close around January 30, 2025.
The proceeds will be used as working capital for general corporate purposes. The company will file a registration statement with the SEC for the resale of shares issuable under the new warrants.
FAQ
What is the current stock price of Silexion Therapeutics (SLXN)?
What is the market cap of Silexion Therapeutics (SLXN)?
